Axel Grothey, MD

Experts discuss the importance of molecular profiling and testing in managing metastatic pancreatic cancer, highlighting advancements in treatment options.

Innovative drug development for pancreatic cancer focuses on KRAS and PRMT5 inhibitors, exploring combinations with chemotherapy for enhanced treatment efficacy.

Experts discuss the impact of NCCN guidelines on pancreatic cancer treatment, highlighting new therapies and future advancements in patient care.

Experts discuss the importance of communication and patient support in managing pancreatic cancer treatment and aligning care goals with patient needs.

Experts emphasize the importance of communication and patient support in managing pancreatic cancer, focusing on aligning treatment goals with personal preferences.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Clinicians discuss managing diarrhea and nutritional support for pancreatic cancer patients, emphasizing the importance of a comprehensive care team.

Discover how NALIRIFOX offers a promising alternative to FOLFIRINOX, enhancing treatment options and reducing toxicities for pancreatic cancer patients.

Healthcare professionals discuss effective strategies for dose reduction in cancer treatment, emphasizing patient reassurance and maintaining treatment efficacy.

Explore strategies for adjusting chemotherapy dosages based on genetic mutations, enhancing patient safety and treatment efficacy in clinical practice.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.

Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.